Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489426 | 0.80 | ADRA1A (0.33) | P2RX7 | |
| SCHEMBL6478515 | 0.75 | GRM4 (0.33) | PLA2G7P2RX7 | |
| SCHEMBL6489375 | 0.75 | GRM4 (0.33) | PLA2G7P2RX7 | |
| SCHEMBL6484250 | 0.71 | FFAR1 (0.33) | PLA2G7 | |
| SCHEMBL6485110 | 0.71 | FFAR1 (0.33) | PLA2G7 | |
| SCHEMBL6476575 | 0.65 | KDM5A (0.40) | P2RX7 | |
| SCHEMBL6485426 | 0.65 | P2RY14 (0.36) | P2RX7 | |
| SCHEMBL6489420 | 0.63 | GRM4 (0.35) | P2RX7 | |
| SCHEMBL6478088 | 0.63 | PTGER4 (0.41) | P2RX7 | |
| SCHEMBL6477100 | 0.63 | CHRM4 (0.43) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PLA2G7 200/4885P2RX7 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.